FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer Meeting Abstract
| Authors: | Isakoff, S. J.; Saura, C.; Calvo, I.; Gil, M. J. G.; Patt, D. A.; Murillo, S. M.; Andersen, J. C.; Cirueios, E.; Fisher, J. G.; Passos-Coelhot, J.; de La Pena, L.; Kapp, A. V.; Gendreau, S.; Chan, W. Y.; Singel, S. M.; Maslyar, D. J.; Baselga, J.; Oliveira, M. |
| Abstract Title: | FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 68s |
| Language: | English |
| ACCESSION: | WOS:000404665401225 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.TPS1105 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS1105 -- Source: Wos |
